DK1326617T3 - Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom - Google Patents
Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeomInfo
- Publication number
- DK1326617T3 DK1326617T3 DK01987669T DK01987669T DK1326617T3 DK 1326617 T3 DK1326617 T3 DK 1326617T3 DK 01987669 T DK01987669 T DK 01987669T DK 01987669 T DK01987669 T DK 01987669T DK 1326617 T3 DK1326617 T3 DK 1326617T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- estra
- acetylphenyl
- dien
- hydroxy
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 title 1
- 206010014733 Endometrial cancer Diseases 0.000 title 1
- 206010014759 Endometrial neoplasm Diseases 0.000 title 1
- 201000009906 Meningitis Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 206010035226 Plasma cell myeloma Diseases 0.000 title 1
- -1 acetylphenyl Chemical group 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 201000000050 myeloid neoplasm Diseases 0.000 title 1
- 230000000708 anti-progestin effect Effects 0.000 abstract 4
- 239000003418 antiprogestin Substances 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000018199 S phase Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099100P | 2000-10-18 | 2000-10-18 | |
| EP00250342 | 2000-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1326617T3 true DK1326617T3 (da) | 2006-12-18 |
Family
ID=26072952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01987669T DK1326617T3 (da) | 2000-10-18 | 2001-10-17 | Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1326617B9 (da) |
| JP (1) | JP2004511523A (da) |
| KR (1) | KR100668024B1 (da) |
| CN (1) | CN1209111C (da) |
| AT (1) | ATE334683T1 (da) |
| AU (2) | AU2002223619B2 (da) |
| BG (1) | BG107744A (da) |
| BR (1) | BR0114696A (da) |
| CA (1) | CA2423020C (da) |
| CY (1) | CY1105745T1 (da) |
| CZ (1) | CZ299823B6 (da) |
| DE (1) | DE60121980T2 (da) |
| DK (1) | DK1326617T3 (da) |
| EA (1) | EA010593B1 (da) |
| EE (1) | EE200300157A (da) |
| ES (1) | ES2269492T3 (da) |
| HK (1) | HK1062273A1 (da) |
| HR (1) | HRP20030388A2 (da) |
| HU (1) | HUP0301433A3 (da) |
| IL (2) | IL154976A0 (da) |
| MX (1) | MXPA03002955A (da) |
| NO (1) | NO20031741L (da) |
| NZ (1) | NZ538347A (da) |
| PL (1) | PL360157A1 (da) |
| PT (1) | PT1326617E (da) |
| SI (1) | SI1326617T1 (da) |
| SK (1) | SK4702003A3 (da) |
| UA (1) | UA76729C2 (da) |
| WO (1) | WO2002032432A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY27301A1 (es) * | 2001-05-25 | 2003-02-28 | Schering Ag | Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| EP2148682A1 (en) * | 2007-04-23 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| CA2683809A1 (en) * | 2007-04-23 | 2008-10-30 | Bayer Schering Pharma Aktiengesellschaft | Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen |
| US20080268041A1 (en) * | 2007-04-23 | 2008-10-30 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| KR102009007B1 (ko) * | 2011-10-04 | 2019-08-08 | 인비비스 파마슈티컬스 인코포레이티드 | 항-프로게스틴 민감성 종양을 확인하고 치료하기 위한 방법 및 시스템 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
-
2001
- 2001-10-17 UA UA2003054311A patent/UA76729C2/uk unknown
- 2001-10-17 HU HU0301433A patent/HUP0301433A3/hu unknown
- 2001-10-17 KR KR1020037005360A patent/KR100668024B1/ko not_active IP Right Cessation
- 2001-10-17 WO PCT/EP2001/012006 patent/WO2002032432A1/en active IP Right Grant
- 2001-10-17 MX MXPA03002955A patent/MXPA03002955A/es active IP Right Grant
- 2001-10-17 EE EEP200300157A patent/EE200300157A/xx unknown
- 2001-10-17 AU AU2002223619A patent/AU2002223619B2/en not_active Ceased
- 2001-10-17 DE DE60121980T patent/DE60121980T2/de not_active Expired - Fee Related
- 2001-10-17 AU AU2361902A patent/AU2361902A/xx active Pending
- 2001-10-17 NZ NZ538347A patent/NZ538347A/en unknown
- 2001-10-17 AT AT01987669T patent/ATE334683T1/de not_active IP Right Cessation
- 2001-10-17 EP EP01987669A patent/EP1326617B9/en not_active Expired - Lifetime
- 2001-10-17 CA CA002423020A patent/CA2423020C/en not_active Expired - Fee Related
- 2001-10-17 IL IL15497601A patent/IL154976A0/xx active IP Right Grant
- 2001-10-17 CZ CZ20031073A patent/CZ299823B6/cs not_active IP Right Cessation
- 2001-10-17 SI SI200130648T patent/SI1326617T1/sl unknown
- 2001-10-17 DK DK01987669T patent/DK1326617T3/da active
- 2001-10-17 ES ES01987669T patent/ES2269492T3/es not_active Expired - Lifetime
- 2001-10-17 EA EA200300479A patent/EA010593B1/ru not_active IP Right Cessation
- 2001-10-17 JP JP2002535670A patent/JP2004511523A/ja active Pending
- 2001-10-17 PL PL01360157A patent/PL360157A1/xx not_active Application Discontinuation
- 2001-10-17 BR BR0114696-3A patent/BR0114696A/pt not_active Application Discontinuation
- 2001-10-17 CN CNB018175694A patent/CN1209111C/zh not_active Expired - Fee Related
- 2001-10-17 SK SK470-2003A patent/SK4702003A3/sk not_active Application Discontinuation
- 2001-10-17 PT PT01987669T patent/PT1326617E/pt unknown
-
2003
- 2003-03-18 IL IL154976A patent/IL154976A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031741A patent/NO20031741L/no not_active Application Discontinuation
- 2003-04-18 BG BG107744A patent/BG107744A/bg unknown
- 2003-05-14 HR HR20030388A patent/HRP20030388A2/hr not_active Application Discontinuation
-
2004
- 2004-07-20 HK HK04105309A patent/HK1062273A1/xx not_active IP Right Cessation
-
2006
- 2006-11-01 CY CY20061101564T patent/CY1105745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1104981T1 (el) | Χρηση των αντιπρογεστερονων για προληψη και αντιμετωπιση των εξαρτωμενων απο ορμονες ασθενειων | |
| DK1326617T3 (da) | Anvendelse af 11beta- (acetylphenyl) -17beta-hydroxy-17alfa- (1,1,2,2-pentafluorethyl) estra-4,9-dien-3-on til fremstilling af et medikament til behandling af brystcancer, ovariecancer, endometrisk caner, myeloma og meningeom | |
| DK1525215T3 (da) | Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner | |
| HRP20050439B1 (en) | New use of dextran sulfate | |
| YU29903A (sh) | Upotreba antiprogestina za indukciju apoptoze u ćeliji | |
| EA200200943A1 (ru) | Гормональная терапия рака молочной железы | |
| JP2004511523A5 (da) | ||
| MXPA05012841A (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. | |
| IS2702B (is) | Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun | |
| YU30103A (sh) | Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti | |
| DE60022517D1 (de) | Zusammensetzung mit steoridisher östrogen wirkung ohne steigerung des brustkrebsrisikos | |
| TW200733955A (en) | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases | |
| ATE288755T1 (de) | Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel | |
| AR039477A1 (es) | Terapia de reemplazo hormonal |